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To accelerate the ﬁght against tuberculosis, major diagnostic challenges need to be addressed urgently. Post-
2015 targets are unlikely to be met without the use of novel diagnostics that are more accurate and can be
used closer to where patients ﬁrst seek care in affordable diagnostic algorithms.
This article describes the efforts by the stakeholder community that led to the identiﬁcation of the high-
priority diagnostic needs in tuberculosis. Subsequently target product proﬁles for the high-priority diagnostic
needs were developed and reviewed in a World Health Organization (WHO)-led consensus meeting.
The high-priority diagnostic needs included (1) a sputum-based replacement test for smear-microscopy; (2) a
non-sputum-based biomarker test for all forms of tuberculosis, ideally suitable for use at levels below microscopy
centers; (3) a simple, low cost triage test for use by ﬁrst-contact care providers as a rule-out test, ideally suitable for
use by community health workers; and (4) a rapid drug susceptibility test for use at the microscopy center level.
The developed target product proﬁles, along with complimentary work presented in this supplement, will help
to facilitate the interaction between the tuberculosis community and the diagnostics industry with the goal to lead
the way toward the post-2015 global tuberculosis targets.
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In 2012, there were an estimated 9 million tuberculosis
cases leading to 1.5 million deaths, the majority of
which were preventable with existing treatments if diag-
nosed early [1]. Major gains have been made in the ﬁght
against tuberculosis over the past decades, and the
world is on track to meet the targets of the 2015 UN
Millennium Development Goal of reversing tuberculo-
sis incidence. Also, all regions except for Africa and Eu-
rope are on track to achieve a reduction in the mortality
rate by 50%. However, to accelerate the ﬁght against
tuberculosis and move towards post-2015 targets and
ﬁnally elimination of this disease, two major challenges
need to be addressed urgently: (1) Each year 3 million pa-
tients, about one third of all tuberculosis cases, are not di-
agnosed or notiﬁed; (2) The emergence of drug resistance
against the main anti-tuberculous drugs is creating a pub-
lic health crisis in many countries around the world.
Early diagnosis of tuberculosis and universal drug-
susceptibility testing are the ﬁrst steps necessary to iden-
tify the adequate treatment for individual patients and
to prevent the spread of disease at the population level.
Novel tests that reach “the missing three million patients”
and curb the epidemic of drug-resistant tuberculosis are
needed. These tests need to have improved performance
characteristics and/or reach lower levels of the health-
care system and be affordable as well as link to the
needs around new drug/regimen development.
This article describes the efforts that lead to the iden-
tiﬁcation of the highest priority diagnostic needs in tuber-
culosis and the consensus-building process that resulted
in target product proﬁles (TPPs) for tests to address those
needs.
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METHODS
Deﬁning a List of Needs
Through interviews with representatives from national tubercu-
losis programs, clinical experts from industrialized, middle, and
low-income countries, researchers, and clinical laboratory ex-
perts, a “wish-list” was compiled deﬁning the most important
diagnostic needs for tuberculosis [2]. In addition, the literature
was searched, and recent reports and position papers were
consulted. A list was then assembled of tests needed to ﬁll im-
portant gaps in the current diagnostic landscape and whose de-
velopment would be feasible in the near future [3].
Prioritization Exercise
Once a list of diagnostic needs was developed, a prioritization
exercise was done in order to establish a rank order of the tests
and to identify those that were perceived of highest priority [3].
Five different predeﬁned expert groups were consulted: patient
and community advocates, ﬁeld practitioners and clinicians,
experts from national tuberculosis programs, modelers, and
market experts. All experts rated the diagnostic needs based
on 10 different criteria having a 5-year time frame for deploy-
ment in mind. The criteria that were evaluated included the pri-
oritization for their respective stakeholders group, the potential
for scale up of a test addressing the respective need, and the
magnitude of the effect of a test on tuberculosis incidence and
mortality reduction as well as the market potential for the test.
TPP Development and Reﬁnement
For the highest rated diagnostic needs, comprehensive TPPs
were developed by McGill University, Montreal, Canada, and
FIND, Geneva, Switzerland. The TPPs were assembled based
on a literature search and interviews with experts and then re-
vised in several rounds with the input provided by researchers,
clinicians, policy makers, test developers, and funders. As a re-
sult of these extended and reiterative consultations, detailed and
comprehensive TPPs were developed. In addition, shorter ver-
sions including only the most important characteristics were
prepared and used for the consensus building process.
Consensus Building
The shortened versions of the TPPs were presented to a large
stakeholder audience that included clinicians, implementers,
and representatives of countries and national tuberculosis pro-
grams in a “Consensus Meeting on high-priority Target Prod-
uct Proﬁles” convened in April 2014, by the World Health
Organization (WHO) on behalf of the Global Laboratory Initia-
tive and the New Diagnostics Working Group of the Stop TB
Partnership. Leading up to the meeting, a Delphi-like process
was used to facilitate consensus building. The shortened TPPs
were sent to all invited meeting participants (excluding individ-
uals working in industry in order to avoid possible bias). Indi-
viduals were asked to rate the level of agreement with each of the
proposed characteristics outlined in the TPPs. It was prespeci-
ﬁed that consensus would be achieved when at least 50% of the
individuals completing the Delphi-survey would agree with the
proposed characteristics. Only characteristics for which less
than 75% of the responders agreed or a distinct subgroup dis-
agreed were ultimately discussed in the consensus meeting. The
ﬁnal TPPs were published by WHO and partners in October
2014 [4]. This article presents the ﬁnal TPPs as they were pub-
lished in the meeting report.
RESULTS
In interviews and reviews of publications, the tuberculosis com-
munity identiﬁed the need for developing several tuberculosis
diagnostic tests in addition to the currently available tools [2].
The list of tests (Table 1) includes triage and screening tests [5],
tests for patients difﬁcult to diagnose (ie, children, patients with
human immunodeﬁciency virus [HIV] and patients with ex-
trapulmonary tuberculosis) [6], a simple non-sputum-based bi-
omarker test for diagnosis of active tuberculosis [7], a molecular
smear-replacement test [8] at the microscopy center level or at
even lower levels of care, drug-susceptibility tests (DST) that
could be done in decentralized or centralized settings [9], a bio-
marker test for diagnosis of a latent tuberculosis infection that
predicts progression to active tuberculosis [10] and a test for
treatment monitoring [11].
Table 1. Identiﬁed Needs for Diagnostic Tests Categorized by
Main Indication
TRIAGE, RULE OUT AND SYSTEMATIC SCREENING
Triage test for those seeking carea
An HIV/ART clinic-based test to rule out active TB
Systematic screening test for active case finding
RAPID TB DIAGNOSIS (WITH OPTIONAL DRUG SUSCEPTIBILITY
TESTING)
Rapid, sputum-based, cartridge-based, molecular test for
microscopy centers (with the option of add-on DST cartridge)a
Rapid biomarker-based instrument-free test for non-sputum
samples (which can also detect childhood and extrapulmonary
TB)a
Multiplexed test for TB and other infectious diseases
NEXT-GENERATION DRUG SUSCEPTIBILITY TEST
Centralized, high-throughput, drug susceptibility test
(incorporating new drugs to support the roll out of new TB Rx
regimens post 2014)
TREATMENT MONITORING TEST
Treatment monitoring test (test for cure)
PREDICTIVE TEST FOR LATENT TB INFECTION
Predictive test for latent TB infection at high risk of active TB
Abbreviations: ART, antiretroviral therapy; DST, drug-susceptibility tests; HIV,
human immunodeficiency virus; TB, tuberculosis.
a Highlights the tests that are being addressed in this article. Target product
profiles for the other identified needs are being developed independent of
the effort described herein by FIND and partners.
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The priority-setting exercise ultimately identiﬁed the follow-
ing tests as the key priorities, which would have the most impact
on incidence and morbidity reduction and potential for market
entry and scale up over the coming 5years [3].
1. A rapid sputum-based test as a replacement for smear-
microscopy (“smear-replacement test”) with or without DST;
2. A rapid non-sputum-based test capable of detecting all
forms of tuberculosis via the identiﬁcation of characteristics bio-
markers or biosignatures (“non-sputum based biomarker test”);
3. A triage test, which should be a simple, low cost test for use by
ﬁrst-contact health care providers as a rule-out test (“triage test”);
More details of the priority setting exercise can be found else-
where [3]. Four TPPs were ultimately developed, dividing up the
rapid sputum-based test as a replacement for smear-microscopy
into one with a DST component (“rapid DST”) and another
one (“smear-replacement test”). The 3 TPPs that address tuber-
culosis detection are presented in this article. The fourth TPP
that addresses the “rapid DST” is presented separately (see Den-
kinger CM et al in this supplement) as it discusses the very com-
plex ﬁeld of drug susceptibility testing.
TPP for a Smear-replacement Test for Tuberculosis Detection
Rationale
Smear microscopy is the most widely used tuberculosis test in
high-burden countries, and its sensitivity limitations are well
known [12]. The sensitivity of newer rapid tools for tuberculosis
detection (eg, Xpert) still does not reach that of culture [13, 14].
More sensitive tests are needed so that patients with tuberculo-
sis can be identiﬁed upon ﬁrst presentation to the health care
system and so that patients with paucibacillary disease (eg,
HIV patients and children) are detected.
Xpert MTB/RIF (“Xpert,” Cepheid, Inc., Sunnyvale, Califor-
nia) has enabled more timely and sensitive diagnosis of tuber-
culosis over smear microscopy and up-front DST for the key
drug (rifampin) in the ﬁrst-line treatment regimen [15–17].
However, the use of Xpert is limited by its cost and infrastruc-
ture requirements (eg, power, temperature controlled environ-
ment), which prohibits its placement and use in most
microscopy centers [18, 19]. The rollout of Xpert has also dem-
onstrated that new diagnostic tools do not necessarily reach ad-
ditional people eligible for testing or increase the overall
number of tuberculosis cases diagnosed, if they are implement-
ed within established care settings (although Xpert does in-
crease the number of bacteriologically conﬁrmed cases) [20].
On the other hand, there is an increasing number of molecular
tests in the pipeline that aim to be more sensitive and are spe-
ciﬁcally designed for use in resource-limited settings such as
microscopy centers or peripheral health clinics [21]. Other as-
says for detection may conceivably be feasible as well (eg, anti-
gen detection), but the molecular pipeline appears to be the
most promising in the near future.
TPP characteristics
A more sensitive smear-replacement test would increase the
number of patients diagnosed with tuberculosis and might re-
duce transmission and morbidity through earlier diagnosis and
treatment (Table 2) [22]. Ideally a test would aim for a better
sensitivity than Xpert for tuberculosis detection and be as
good as liquid culture (ie, diagnostic sensitivity of >95% in com-
parison to culture; analytical sensitivity of less than 4.5 genome
equivalents/reaction and <10e2 CFU/assay on one sample).
Such a test could obviate further need for culture in drug-
susceptible tuberculosis and potentially improve the trust of cli-
nicians and patients in the diagnostic performance of tests and
thereby reduce empiric treatment and overtreatment [24].
Modeling work has demonstrated that even a test with per-
formance characteristics better than smear (50% detection of
smear-negative) yet inferior to Xpert, if employed at microscopy
centers and combined with good linkage to treatment, would
result in a reduction in transmission over deployment of Xpert
at a district level [22]. Whether up-front resistance testing such
as detection of rifampin resistance in Xpert is beneﬁcial will de-
pend on the local epidemiology of drug-resistance and the
trade-offs made by including DST (eg, in respect to time to re-
sult). A test at the level of a microscopy center would also lever-
age the existing treatment infrastructure for drug-susceptible
tuberculosis that is already in place in these settings. Further-
more, if a smear-replacement test can also be used for treatment
monitoring (eg, through detecting viable bacteria), it would be
able to completely replace smear microscopy and would be
more likely to be adopted by tuberculosis programs.
A sputum-smear replacement test should ideally have a fast
turn-around time and allow for batching as well as random access
to rapidly inform a treatment decision at the time of the ﬁrst visit
and link to further care [25, 26].Due to conditions that prevail in
microscopy centers in high-burden countries, a robust test with
very simple sample preparation andminimal operational require-
ments will be necessary [8, 18]. Minimal sample handling (ie,
total hands-on steps after obtaining sample) and no precision
volume control and precision time steps should be required to
ensure that the test is feasible with the level of expertise and train-
ing that can be expected at microscopy centers [8, 18].
Continuous power is not always available at microscopy cen-
ters in high tuberculosis burden countries; therefore, a battery op-
erated device with charge possibility (conceivably through solar
power) would be most ideal in order for a test to ﬁt the entire
breadth of settings in microscopy centers [8, 18]. High environ-
mental temperatures and high humidity (up to 50°C and 90% hu-
midity) are often a problem in countries where tuberculosis is
endemic. Dusty environments are common and adequate protec-
tion of optics and moving parts should be considered [27].Main-
tenance and calibration require special attention to ensure
functionality of equipment particularly at peripheral centers. The
average time to equipment/module failure should ideally be more
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Table 2. TPP for a Smear-replacement Test for Tuberculosis Detection
Characteristic Optimal Requirements Minimal Requirements
Scope
Goal To develop a sputum-based test for detecting pulmonary TB at the microscopy-center level of the
health-care system to support the initiation of TB therapy during the same clinical encounter or
the same day
Target population Target groups are all patients suspected of having pulmonary TB who are able to produce sputum,
in countries with a medium prevalence to a high prevalence of TB as defined by WHOa
Target user of the testb Health-careworkers with a minimum amount of training (that is, with skills that are similar to or less
demanding than those needed for performing smear microscopy)
Setting (level of the health-care system) Microscopy-center level (primary health-care centers with attached peripheral laboratories) or
higher levels of the health-care system
PERFORMANCE CHARACTERISTICS
Diagnostic sensitivityb Sensitivity should be >95% for a single test
when compared with culture (for smear-
negative cases it should be >68%; for smear-
positive it should be 99%)
Sensitivity should be >80% for a single test
when compared with culture (for smear-
negative cases it should be >60%; for smear-
positive it should be 99%)
Diagnostic specificityb >98% specificity when compared with culture
Possibility of using test for treatment
monitoring
Yes: a test that is able to replace smear
microscopy and also be used to monitor
treatment is more likely to be adopted and
more likely to completely replace smear
microscopy
No
OPERATIONAL CHARACTERISTICS
Manual preparation of samples (steps
needed after obtaining sample)
No steps or 1 step; precise volume control and
precise timing should not be required
A maximum of 2 steps; precise volume control
and precise timing should not be required
Reagent integration All reagents should be contained in a single
device
A maximum of 2 external reagents should be
required; these should be part of test kit
Data export (connectivity and
interoperability)
Integrated ability for all data to be exported
(including data on use of the device, error
rates and rates of invalid tests, and
personalized, protected results) over a USB
port and network
Integrated ability for all data to be exported
(including data on use of the device, error
rates and rates of invalid tests, and non-
personalized results) over a USB port
Time to resultb <20 min <2 h
Power requirements Battery operated with recharging capability and a circuit protector
Maintenance and calibrationb Preventative maintenance and calibration
should not be needed until after 2 y or 5000
samples; only simple tools and minimal
expertise should be required; an alert to
indicate when maintenance is needed should
be included; the device should be able to be
calibrated remotely or no calibration should be
required
Preventative maintenance should not be
needed until after 1 y or 1000 samples; only
simple tools and minimal expertise should be
required; an alert to indicate when
maintenance is needed should be included;
the device should be able to be calibrated
remotely, should calibrate itself or no
calibration should be required
Operating temperature and humidity
level
Between +5°C and +50°C with 90% humidity Between + 5°C and +40°C with 70% humidity
Reagent kit – storage, stability, and
stability during transport
2 years at 0°C to +50°C with 90% humidity;
should be able to tolerate stress during
transport (72 h at +50°C); no cold chain
should be required
12 months at 0°C to +40°C with 70% humidity;
should be able to tolerate stress during
transport (72 h at +50°C); no cold chain
should be required
Internal quality control Full internal process controls are necessary,
including controls for sample processing and
amplification (for NAAT)
PRICING
Price of individual testb (costs of reagent
only; after scale-up; ex-works
[manufacturing costs only, excluding
shipping])
<US$ 4.00 for detecting TB <US$ 6.00 for detecting TB
Capital costs for instrumentb <US$ 500 per module <US$ 1400 per module
Adapted with permission from WHO consensus meeting report on TPPs [4]
Abbreviations: NAAT, nucleic acid amplification test; TB, tuberculosis; TPPs, target product profiles; WHO, World Health Organization.
a High-prevalence countries are thosewith >40 cases per 100 000 population; medium-prevalence countries are thosewith 20–40 cases per 100 000 population; and
low-prevalence countries are those with <20 cases per 100 000 population [23].
b These characteristics were considered to be the most important, and specific consensus was asked for and reached through a Delphi survey.
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than 2 years, and a maintenance alert should indicate the need for
preventative maintenance as it is unlikely that the same person will
always handle the device and records will be kept on duration of use
of a device [28].Only simple tools and minimal expertise should be
required for maintenance and repair of the equipment given the
difﬁculty of service visits in peripheral settings [8, 18]. The scale
at which a new test is adopted will depend substantially on how
well it meets the speciﬁed operational characteristics.
TPP for a Non-sputum-based Biomarker Test for Tuberculosis
Detection
Rationale
A highly sensitive test based on a biological sample other than
sputum (such as urine, blood, saliva, or exhaled air) suitable for
implementation at lower levels of care would conceivably help
shorten the delay before diagnosis and enable early treatment
(and thus reduce morbidity, mortality and transmission) [29,
30] (Table 3). A non-sputum based sample could also enable the
diagnosis of extrapulmonary tuberculosis (EPTB) and tubercu-
losis in children as well as the diagnosis in patients presenting in
an earlier stage of the disease (eg, patients who do not have a
productive cough to provide a sputum) [25, 31].
TPP characteristics
A non-sputum based biomarker test ideally should be at least as
accurate as Xpert 98% sensitive for smear-positive, culture-
positive pulmonary tuberculosis (PTB), and 68% sensitive for
smear-negative, culture-positive PTB in adults; however, any
improvement over smear microscopy could be of value if the
test has operational characteristics that make it easy to perform
and uses a non-sputum-based sample [32]. For children, a test
sensitivity equal or better than 66% for intrathoracic tuberculo-
sis and equal or better than 80% for extrapulmonary tuberculo-
sis (EPTB) in adults would be optimal, as this can currently be
achieved on the appropriate samples with Xpert [1, 6, 33]. Sim-
ilar to Xpert, the speciﬁcity of the test should at least be 98%
compared against a microbiological reference standard. Ideally
the test should be suitable for use at lower levels of the health-
care system where it can reach more patients, and it should ide-
ally not require laboratory facilities [22, 34]. Given the deploy-
ment at lower levels of the health-care system, an instrument
free test would be ideal, but a small (eg, handheld) device is ac-
ceptable and would conceivably add beneﬁts (eg, connectivity).
The operational characteristics deﬁned for a smear-replacement
test at the microscopy center need to be met at a minimum.
TPP for a Community-based Triage/Referral Test for
Identiﬁcation of Tuberculosis Suspects
Rationale
Most individuals who present themselves to health facilities
with symptoms suggestive of tuberculosis do not have tubercu-
losis. In order to rule out tuberculosis quickly a low-cost triage
test is necessary. Only triage test positive patients will then re-
quire conﬁrmatory testing [5, 35] (Table 4).
TPP characteristics
A triage test needs to be a simple, low-cost test with high sensi-
tivity for use by ﬁrst-contact providers in the community (eg,
community health workers). Such a test can rule out tuberculosis
when the result is negative. Individuals with a positive result are
directed to further evaluation with a conﬁrmatory test (eg, Xpert).
Sensitivity of a triage test should ideally be as good as that of the
conﬁrmatory test (>95% of conﬁrmatory test) as otherwise pa-
tients would be missed by the test and the strategy of testing all
patients with the conﬁrmatory test would theoretically result in a
higher case notiﬁcation rate. However, if a triage test is done at
lower levels of care and is easier to do, conceivably more people
suspected of having tuberculosis will be tested. Consequently, the
test might increase the number of tuberculosis patients identiﬁed
even if its sensitivity is lower than that of the conﬁrmatory test.
Therefore, the minimal sensitivity in the TPP was deﬁned to be
greater than 90% compared to the conﬁrmatory test.
A triage test might also conceivably diagnose EPTB. For con-
ﬁrmatory testing, a molecular test or culture on an aspirate or
biopsy would then be necessary (eg, a biopsy for lymph node
tuberculosis). The speciﬁcity requirement for a triage test needs
to consider the tuberculosis prevalence in the population tested,
but consensus was reached that it should be optimally at least
80% and minimally at least 70%. The speciﬁcity of the test is
one of the main drivers of the cost-effectiveness of an implemen-
tation strategy. The lower the speciﬁcity of the triage test, the
higher the number of conﬁrmatory tests necessary and therefore
the lower the cost of a triage test needs to be to result in a cost-
effective testing strategy [5].
For successful implementation at the community level, a tri-
age test should ideally use an easily accessible sample (eg, urine,
ﬁnger stick blood). The test should optimally be device-free or if
a device is needed it should at least be battery-operated [8, 18].
The ideal time-to-result (including sample preparation and
processing time) has not been studied; however, a rapid test is
more likely to be integrated within the work ﬂow and result in
same visit decision making.
The main characteristics of these TPPs were discussed and
agreed upon in the “Consensus Meeting on high-priority Target
Product Proﬁles” convened by the World Health Organization
on behalf of the Global Laboratory Initiative and the New Diag-
nostics Working Group of the Stop TB Partnership in April
2014 and published in October 2014 [4].
DISCUSSION
Novel tests are needed to reach “the missing three million pa-
tients” and curb the epidemic of drug-resistant tuberculosis.
These tests need to have improved performance characteristics,
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Table 3. TPP for a Rapid Non-sputum-based Biomarker Test for Tuberculosis Detection
Characteristic Optimal Requirements Minimal Requirements
SCOPE
Goal To develop a rapid biomarker-based test that can diagnose pulmonary TB and optimally also
extrapulmonary TB using non-sputum samples (for example, urine, blood, oral mucosal
transudates, saliva, exhaled air) for the purpose of initiating TB treatment during the same
clinical encounter or on the same day
Target population Target groups are adults and children including those who are HIV-positive and suspected of
having active pulmonary TB or extrapulmonary TB in countries with a medium prevalence to a
high prevalence of TB as defined by WHOa
Target user of the testb Health-care workers with a minimum of
training
Trained microscopy technicians
Setting (level of the health-care system) Health posts without attached laboratories
(that is, levels below microscopy centers)
or higher levels of the health-care system
Primary health-care clinics with attached
laboratories; peripheral microscopy centers or
higher levels of the health-care system
PERFORMANCE CHARACTERISTICS
Diagnostic sensitivity for pulmonary TB in
adultsb
Sensitivity should be ≥98% for smear-
positive culture-positive pulmonary TB,
and ≥68% for smear-negative culture-
positive pulmonary TB in adults (that is,
sensitivity should be similar to that of the
Xpert MTB/RIF assay)
Overall pooled sensitivity should be ≥80% in
adults with HIV infection
Overall sensitivity should be ≥65% but should be
>98% among patients with smear-positive
culture-positive pulmonary TB (that is,
sensitivity should be similar to that of smear
microscopy)
Overall pooled sensitivity should be better than
the sensitivity of smear microscopy in adults
with HIV infection
Diagnostic sensitivity for extrapulmonary
TB in adults
Ideally, sensitivity should be ≥80% for all
forms of microbiologically confirmed
extrapulmonary TBc,d
Diagnosis of extrapulmonary TB is an important
need, and a test that can diagnose
extrapulmonary TB in addition to pulmonary TB
will have significant benefits for individual
patients; additionally, it is likely to be better
accepted in the community of care providers.
No lower range of sensitivity was defined
Diagnostic sensitivity in children Sensitivity for childhood intrathoracic TB
should be ≥66% for microbiologically
confirmed TB (that is, similar to the
sensitivity of the Xpert MTB/RIF assay)e
Diagnosis of childhood TB is an important need,
and a test that improves the diagnosis of TB in
children will have significant benefits for
individual patients; additionally, it is likely to be
better accepted in the community of care
providers.
No lower range of sensitivity was defined
Diagnostic specificityb At least as specific as the Xpert MTB/RIF assay for detecting pulmonary TB, extrapulmonary TB
and childhood TB (that is, the test should have 98% specificity when compared against a
microbiological reference standard); the test should distinguish between active TB and latent or
past infection
OPERATIONAL CHARACTERISTICS
Sample type Not invasive or minimally invasive, non-sputum samples (such as, urine, blood, oral transudates,
saliva, exhaled air)
Manual preparation of samples (steps
needed after obtaining sample)
Sample preparation should be integrated or
manual preparation should not be required
A limited number of steps only; precise
measuring should not be needed for any
step (such as precise measuring of volumes
or time)
Time to resultb <20 min including time spent preparing the
sample
<1 h including time spent preparing the sample
Instrument and power requirement No instrument needed Small, portable or hand-held instrument (weighing
<1 kg) that can operate on battery or solar
power in places where power supplies may be
interrupted
Maintenance and calibrationb Disposable, no maintenance required Preventative maintenance should not be needed
until after 1 y or >1000 samples; only simple
tools and minimal expertise should be required;
an alert to indicate when maintenance is
needed should be included; the instrument
should be able to be calibrated remotely or no
calibration should be needed
Operating temperature and humidity level Between +5°C and +50°C with 90%
humidity
Between +5°C and +40°C with 70% humidity
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reach lower levels of the health-care system and reduce cost of
diagnostic algorithms as well as link to the needs around new
drug/regimen development. TPPs are important to specify
end-users needs and target speciﬁcations for performance and
operational characteristics that product developers should meet.
While the TPPs outlined here are all based on a large number of
interviews, discussions and extensive literature consultation,
still many of the characteristics rely on assumptions and the
consensus of expert opinion. Also, the TPPs specify the needs
across a wide spectrum of settings with substantial potential dif-
ferences. While modeling might be of beneﬁt in this context, the
understanding of the most essential parameters, particularly for
tests that would reach a patient population that is currently not
reached by tests (eg, triage test), is limited and modeling outputs
are often restricted to deﬁning the key drivers of impact and set-
ting boundaries for those characteristics in sensitivity analyses
[5, 36]. As further data become available from operational re-
search and modeling, the outlined TPPs may require reﬁne-
ment. Particularly, deﬁning the acceptable costs is difﬁcult
and transparent discussions around diagnostic pricing, cost
structure and hidden costs on the one hand and affordability
and cost-effectiveness on the other hand are necessary.
New tuberculosis diagnostic tests able to improve tuberculo-
sis detection for EPTB, tuberculosis in children and other forms
of paucibacillary tuberculosis could be of great beneﬁt for indi-
vidual patient management [33, 37, 38]. An outstanding ques-
tion in this context concerns which reference standard should
be considered to assess test accuracy for the diagnosis of these
forms of the disease. Indeed microbiological culture, commonly
used as the reference standard for establishing a deﬁnitive diag-
nosis of tuberculosis, performs poorly in children and EPTB pa-
tients [39–41]. Therefore, test accuracy for the detection of
EPTB and tuberculosis in children should be evaluated against
a composite reference standard including multiple diagnostic
methodologies as well as clinical diagnosis criteria. A composite
reference standard for the evaluation of diagnostics for child-
hood tuberculosis has been deﬁned by an international expert
panel and is currently being updated and revised based on latest
available evidence [6, 42].
Furthermore, the development of TPPs only represents a ﬁrst
step to address test developers’ needs. The next question that
needs to be addressed is the current and potential volume and
market for the new tests. This is a key issue for test developers as
they consider an investment in this ﬁeld [43]. To estimate the
potential market, one ﬁrst has to assess the currently served
market. The last large-scale market assessment for tuberculosis
diagnostics was performed by FIND and TDR in 2006 [44].
More recently market assessments were done for 4 BRICS coun-
tries (Brazil, South Africa, China, and India) under the lead of
McGill University in collaboration with FIND, UNITAID, the
New Diagnostics Working Group of the Stop TB Partnership,
and multiple country level partners. The work will be docu-
mented in separate publications, with the ﬁrst article published
being the market assessment for Brazil [45]. An assessment of
Table 3 continued.
Characteristic Optimal Requirements Minimal Requirements
Result capturing, documentation, data
display
An instrument-free test with the ability to
save results using a separate, attachable
reader
The test menu must be simple to navigate; the
instrument should have an integrated LCD
screen, simple keypad or touch screen, and the
ability to save results using either the
instrument or a separate reader
Internal quality control Internal controls should be included for
processing the sample and detecting TB
Internal control included only for processing the
sample
PRICING
Price of individual testb (costs of reagents
and consumables only; after scale-up;
ex-works [manufacturing costs only,
excluding shipping])
<US$ 4.00 <US$ 6.00
Adapted with permission from WHO consensus meeting report on TPPs [4].
Abbreviations: HIV, human immunodeficiency virus; LCD, liquid crystal display; TB, tuberculosis; TPPS, target product profiles; WHO, World Health Organization.
a High-prevalence countries are thosewith >40 cases per 100 000 population; medium-prevalence countries are thosewith 20–40 cases per 100 000 population; and
low-prevalence countries are those with <20 cases per 100 000 population [23].
b These characteristics were considered to be the most important, and specific consensus was asked for and reached through a Delphi survey.
c The sensitivity for detecting extrapulmonary tuberculosis should also be tested against a composite reference standard that includes culture with or without a
nucleic acid amplification test, histology, smear microscopy, biochemical testing, presenting signs, and response to treatment with anti-tuberculosis therapy,
depending on site of infection. Xpert MTB/RIF testing has an estimated sensitivity for diagnosing tuberculosis of 84% for lymph node aspirates or other tissue
samples, and 55% sensitivity for samples of cerebrospinal fluid, when compared with a composite reference standard, but Xpert MTB/RIF testing requires
invasive samples [1].
d Xpert MTB/RIF has an estimated sensitivity for microbiologically confirmed tuberculosis of 85% for detecting tuberculosis in lymph node aspirates or other tissue
samples, 80% for cerebrospinal fluid, and 44% for pleural fluid but testing requires invasive samples (from aspiration, biopsy, lumbar puncture or thoracentesis).
e The test’s sensitivity in children should be evaluated against a composite reference standard as defined by an international panel of experts [6].
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Table 4. TPP for a Community-based Triage/Referral Test for Identiﬁcation of TB Suspects
Characteristic Optimal Requirements Minimal Requirements
SCOPE
Goal To develop a test that can be used during a patient’s first
encounter with the health-care system to identify
patients with any symptoms of or risk factors for
active TB, including patients coinfected with HIV,
those who do not have TB and those who need
referral for further confirmatory testing
To develop a test that can be used during a patient’s first
encounter with the health-care system to identify
patients with any symptoms of or risk factors for
active pulmonary TB, including patients coinfected
with HIV, those who do not have TB and those who
need referral for further confirmatory testing
Target population Adults and children with signs and symptoms of active
TB at any site in countries with a medium prevalence
to a high prevalence of TB as defined by WHOa
Adults and children with signs and symptoms of active
pulmonary TB in countries with a medium
prevalence to a high prevalence of TB as defined by
WHOa
Target user of the testb Community health workers and informal providers who
have had a minimum of training
Health workers trained to the level of auxiliary nurses
Setting (level of the health-care
system)
Community level or village level or higher levels of the
health-care system
Health posts and primary-care clinics or higher levels of
the health-care system
PERFORMANCE CHARACTERISTICS
Diagnostic sensitivityb Overall sensitivity should be >95% when compared
with the confirmatory test for pulmonary TB;c no
lower range of sensitivity was defined for
extrapulmonary TBd
Overall sensitivity should be >90% compared with the
confirmatory test for pulmonary TBc
Diagnostic specificityb Specificity should be >80% compared with the
confirmatory test
Specificity should be >70% compared with the
confirmatory test
OPERATIONAL CHARACTERISTICS
Sample type Non-sputum samples (such as urine, oral mucosal
transudates, saliva, exhaled air or blood from a finger-
stick)
Sputum; non-sputum samples are preferred (such as
urine, oral mucosal transudates, saliva, exhaled air, or
blood from a finger-stick; imaging technology
Manual preparation of samples
(steps needed after obtaining
sample)
Sample preparation should be integrated or manual
preparation should not be required (excluding waste
disposal); precise timing andmeasuring should not be
required
2 steps (excluding waste disposal); precise timing and
measuring should not be required
Time to resultb <5 min <30 min
Instrument and power
requirement
None Small, portable or hand-held device (weighing <1 kg);
should have an option for battery power or solar
power
Maintenance and calibrationb Disposable, no maintenance required Preventative maintenance should not be needed until
after 1 y or 1000 samples; only simple tools and
minimal expertise should be required; an alert to
indicate when maintenance is needed should be
included; the device should be able to be calibrated
remotely, should calibrate itself, or no calibration
should be required
Operating temperature and
humidity level
Between +5°C and +50°C with 90% humidity Between + 5°C and +40°C with 70% humidity
Result capturing, documentation
and data display
An instrument-free test with visual readout and with the
ability to save results using a separate, attachable
reader
The test menu must be simple to navigate; the
instrument should have an integrated LCD screen, a
simple keypad or touch screen, and the ability to save
results using either the instrument or a separate
reader
Internal quality control Internal controls should be included for processing the
sample and detecting TB
Internal control included only for processing the sample
PRICING
Price of individual testb (costs of
reagents and consumables
only; after scale-up; ex-works
[manufacturing costs only,
excluding shipping])
<US$ 1.00 <US$ 2.00
Adapted with permission from WHO consensus meeting report on TPPs [4].
Abbreviations: HIV, human immunodeficiency virus; LCD, liquid crystal display; TB, tuberculosis; TPP, target product profiles; WHO, World Health Organization.
a High-prevalence countries are thosewith >40 cases per 100 000 population; medium-prevalence countries are thosewith 20–40 cases per 100 000 population; and
low-prevalence countries are those with <20 cases per 100 000 population [23].
b These characteristics were considered to be the most important, and specific consensus was asked for and reached through a Delphi survey.
c The performance characteristics of the triage test need to match those of the confirmatory test that will be used.
d The sensitivity of the triage test should be compared with the sensitivity of a composite reference standard (that includes culture with or without a nucleic acid
amplification test, histology, smear microscopy, biochemical testing, presenting signs and response to treatment with anti-tuberculosis therapy, depending on site of
infection) to account for the fact that the test may detect cases of early tuberculosis or extrapulmonary tuberculosis in cases in which a standard microbiological
reference standard might not perform well.
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the market for a potential smear-replacement test has also been
published [12]. The market potential for the novel tests de-
scribed in the TPPs above was assessed based on the served
available market combined with country speciﬁc epidemiologi-
cal data. The results of these market projections are presented in
this supplement in a separate article (see Kik et al [3, 12]).
The achievable volume for a test will be part of the consider-
ation when test developers deﬁne the test price. For countries
the question will be whether the rollout of a test is possible
given the available budget. This question can be answered by
considering the number of patients that will be tested, the likely
algorithms with which a test will be used, and the available
country budget based on the current spent [46]. The results
may on the one hand inform test developers as they consider
the price point for a novel test and on the other hand it will in-
form national programs, donors, and funders. Such an exercise
was undertaken considering the 4 novel TPPs and is presented
here in a separate article (Pantoja et al [46]).
In summary, this article describes 3 out of 4TPPs that were
identiﬁed as the highest priority by the tuberculosis community
and the consensus that was reached on the most important per-
formance and operational characteristics. Our work, together
with complementary work presented in this supplement, aims
to facilitate the interaction between the tuberculosis community
and the diagnostics industry with the goal of leading the ﬁeld
toward achieving the post-2015 global targets [47].
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